Zacks May article and other thoughts
Zacks (as Anita Dushyanth) in SeekingAlpha article had a price target of $1 in May based on the therapeutic laser only (the new TLC-2000 to be commercially launched later in 2014 as a successor to the current TLC-1000).
The article also discusses the PDCs & TLC-3000 laser and gives some background, worth a read.
https://seekingalpha.com/article/2206433-initiation-report-for-theralase-technologies.
[Zacks SCR don't get paid for these articles, they say, but are touting for business for their Investment arm?]
There's also a couple of short CEO interviews on YouTube and the Midas letter has an hour audio interview that goes back to how it all started.
I like the non-toxic aspects of the PDCs, like the new immunotherapy approaches, we are finally moving away from toxicity caused by chemo and radiation, and those two latter ones also damage the natural immune system, which really is looking as our best defence especially once it can be trained to fight cancerous cells that it now misses (and thus my equal interests in the immunotherapy approaches, well the non-patient-specific ones anyway).
Maybe the two will work together (PDCs to speedily remove tumours, immunotherapy to mop-up remaining cancerous cells); but given the just-reported "memory" immune effect of the PDCs maybe PDCs will work alone, I'm certainly keen to hear any ideas as to what mechanism this immune/memory effect uses (how long it lasts, how well it copes with mutating cancer cells, is the immune response otherwise harmless etc).
If there has been an accidental discovery of a new way of training the immune system then (given IP protection is in place?) this has to be a $Bs company (eventually, assuming not sold early etc). As the NR says "Technology that is able to rapidly and effectively destroy "patient-specific" cancer cells, prevent their recurrence and provide long lasting protection against local and distant metastasis, offers immense clinical benefit to cancer patients and the facilities that treat their disease. ", we just don't know much about how the PDCs are actually doing it.
MD